EPISODE · Feb 4, 2026 · 13 MIN
AbbVie Q4 2025 Earnings: Beyond the Humira Horizon
from Daily Market Download · host Daily Market Download
AbbVie reported record 2025 revenue of $61.2B, led by the surging immunology drugs Skyrizi and Rinvoq. Despite Humira erosion, management issued strong 2026 guidance. The firm also signed a U.S. government agreement to invest $100B in R&D while ensuring drug affordability.
What this episode covers
AbbVie reported record 2025 revenue of $61.2B, led by the surging immunology drugs Skyrizi and Rinvoq. Despite Humira erosion, management issued strong 2026 guidance. The firm also signed a U.S. government agreement to invest $100B in R&D while ensuring drug affordability.
NOW PLAYING
AbbVie Q4 2025 Earnings: Beyond the Humira Horizon
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m